Skip to main content
Eleftheria Zeggini
Helmholtz Zentrum München | Jan Roeder

Eleftheria Zeggini

Director Institute of Translational Genomics, Program Spokesperson for our program ENABLE

"Our research leverages big data in genetics and genomics for medically important human traits. We aim to translate insights from genomics into mechanisms of disease development and progression, shortening the path to translation and empowering precision medicine."

 

"Our research leverages big data in genetics and genomics for medically important human traits. We aim to translate insights from genomics into mechanisms of disease development and progression, shortening the path to translation and empowering precision medicine."

 

Research

Eleftheria works in the field of Translational Genomics. Her team develops and applies robust statistical and computational tools to integrate information gleaned from deep molecular, genomics and epidemiological approaches to address important biomedical research challenges.

Academic Journey

"In 2018 I joined Helmholtz Munich, where I am founding director of the Institute of Translational Genomics. I am interested in dissecting the role of sequence variation in human health and disease by coupling high-throughput sequencing technologies with the study of diverse populations and strategies linking electronic health records to genomics. Our activities are underpinned by the integration of big multi-omics data, and by the development of computational and statistical approaches for the next generation of translational genomics studies.

I am committed to developing early career researchers. I promote diversity and inclusion, and have a strong interest in capacity building.

I am a Liesel Beckmann Distinguished Professor and hold the Chair of Translational Genomics at Technical University of Munich (TUM) School of Medicine."

Skills

Big dataMulti-omicsGenomicsBiomedical researchPrecision medicineDigital Health

Professional Background

2020

Professor at the TUM School of Medicine, Technical University Munich and Klinikum Rechts der Isar

2018

Director ITG at Helmholtz Munich

2008-2018

Group Leader, Wellcome Sanger Institute, Hinxton, UK

2006-2008

Wellcome Research Career Development Fellow, Wellcome Centre for Human Genetics, University of Oxford, UK

2004-2006

Post Doctoral Research Associate in Statistical Genetics, Wellcome Centre for Human Genetics, University of Oxford, UK

2003-2004

Post Doctoral Research Associate, Centre for Integrated Genomic and Medical Research, University of Manchester, UK

2003

PhD in Immunogenetics of Juvenile Arthritis at the School of Medicine, University of Manchester, UK

1999

Bachelor of Science (Hons) in Biochemistry at University of Manchester Institute of Science and Technology, UK

Honors and Awards

  • 2022: National Representative to the EMBL Council

  • 2020: Elected Fellow of the Academy of Medical Sciences, UK

  • 2020: Argo Award for Distinguished Greeks Abroad

  • 2018: Honorary Senior Fellow, University of Cambridge

  • 2018: Honorary Professor, University of Bristol

Variante: Gold Star Awards Luxury Background
suppa - stock.adobe.com

Selected Publications

See all

2021 Cell

Boer CG*, Hatzikotoulas K*, Southam L*, Stefánsdóttir L, Zhang Y, Coutinho de Almeida R, Wu TT, Zheng J, Hartley A, Teder-Laving M, Skogholt AH, Terao C, Zengini E, Alexiadis G, Barysenka A, Bjornsdottir G, Gabrielsen ME, Gilly A, Ingvarsson T, Johnsen MB, Jonsson H, Kloppenburg M, Luetge A, Lund SH, Mägi R, Mangino M, Nelissen RRGHH, Shivakumar M, Steinberg J, Takuwa H, Thomas LF, Tuerlings M; arcOGEN Consortium; HUNT All-In Pain; ARGO Consortium; Regeneron Genetics Center, Babis GC, Cheung JPY, Kang JH, Kraft P, Lietman SA, Samartzis D, Slagboom PE, Stefansson K, Thorsteinsdottir U, Tobias JH, Uitterlinden AG, Winsvold B, Zwart JA, Davey Smith G, Sham PC, Thorleifsson G, Gaunt TR, Morris AP, Valdes AM, Tsezou A, Cheah KSE, Ikegawa S, Hveem K, Esko T, Wilkinson JM, Meulenbelt I, Lee MTM, van Meurs JBJ, Styrkársdóttir U, Zeggini E *contributed equally

Deciphering osteoarthritis genetics across 826,690 individuals from 9 populations.